The BioMedWire Podcast
En yeni bölüm
The BioMedWire Podcast: Quantum BioPharma (NASDAQ: QNTM) Executive…
The BioMedWire Podcast: Quantum BioPharma (NASDAQ: QNTM) Executive…
Bu podcast hakkında
CryptoCurrencyWire is a regular guest on the Wild West Crypto Show and other shows to share press releases of interest within the blockchain space.
Bölümler
136 bölümden en yeni 20 bölüm
- The BioMedWire Podcast: Quantum BioPharma (NASDAQ: QNTM) Executive Co-Chair Anthony Durkacz Returns · 16 dk · Bölüm 136AUSTIN, Texas, September 30, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to…
- The BioMedWire Podcast: Quantum BioPharma (NASDAQ: QNTM) Executive Co-Chair Anthony Durkacz Returns [Video Edition] · 16 dk · Bölüm 135AUSTIN, Texas, September 30, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to…
- The BioMedWire Podcast Featuring Dr. Ehud Geller CEO of Regentis Biomaterials (NYSE American: RGNT) · 29 dk · Bölüm 134AUSTIN, Texas, September 18, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to…
- The BioMedWire Podcast Featuring Dr. Ehud Geller, CEO of Regentis Biomaterials (NYSE American: RGNT) [Video Edition] · 29 dk · Bölüm 133AUSTIN, Texas, September 18, 2026 – via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to…
- A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach · 20 dk · Bölüm 132BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what…
- A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach [Video Edition] · 20 dk · Bölüm 131BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) drugs on the market today can slow the disease down, but none of them stop it, and none of them give patients back what…
- The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) · 37 dk · Bölüm 130Disseminated on behalf of Onco-Innovations Ltd., may include paid advertisements. AUSTIN, Texas, September 10, 2026 – via IBN – IBN, a multifaceted communications organization…
- The BioMedWire Podcast Featuring Dr. Islam Mohamed, Chief Medical Officer of Onco-Innovations Ltd. (CBOE CA: ONCO) (OTCQB: ONNVF) [Video Edition] · 37 dk · Bölüm 129Disseminated on behalf of Onco-Innovations Ltd., may include paid advertisements. AUSTIN, Texas, September 10, 2026 – via IBN – IBN, a multifaceted communications organization…
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis · 21 dk · Bölüm 128BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people…
- Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis [Video Edition] · 21 dk · Bölüm 127BioMedWire Editorial Coverage: Multiple sclerosis (“MS”) robs people of control over their own bodies — slowly, relentlessly and without a cure. More than 2.9 million people…
- Next-Generation DNA Repair Therapies Open New Frontiers in Oncology · 21 dk · Bölüm 126BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by…
- Next-Generation DNA Repair Therapies Open New Frontiers in Oncology [Video Edition] · 21 dk · Bölüm 125BioMedWire Editorial Coverage: Cancer research is entering one of its most dynamic periods in decades. The class of drugs known as DNA Damage Response inhibitors, which work by…
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments · 21 dk · Bölüm 124BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing…
- How Advanced Drug Delivery Could Improve Existing Cancer Treatments [Video Edition] · 21 dk · Bölüm 123BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing…
- BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) · 17 dk · Bölüm 122Disseminated on behalf of Quantum BioPharma, may include paid advertisements. AUSTIN, Texas, June 2, 2026 – via IBN – IBN, a multifaceted communications organization engaged in…
- BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) [Video Edition] · 17 dk · Bölüm 121Disseminated on behalf of Quantum BioPharma, may include paid advertisements. AUSTIN, Texas, June 2, 2026 – via IBN – IBN, a multifaceted communications organization engaged in…
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities · 20 dk · Bölüm 120BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain…
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities [Video Edition] · 20 dk · Bölüm 119BioMedWire Editorial Coverage: The human brain remains one of the most protected, and difficult to treat, organs in the body. At the center of this challenge is the blood-brain…
- The Next Generation of the GLP-1 Revolution Is Already Underway · 22 dk · Bölüm 118BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of…
- The Next Generation of the GLP-1 Revolution Is Already Underway [Video Edition] · 22 dk · Bölüm 117BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) have become two of the most pressing healthcare challenges worldwide, driving rising rates of…








